Axol Bioscience
PrivateLast Round
Early Funding
Jan 13, 2026
Est. Valuation
$36.05M
Total Funding Raised
$17.01M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Axol Bioscience is a biotechnology company that provides human induced pluripotent stem cell (iPSC) technologies, specializing in the manufacture of iPSC-derived cells and the delivery of laboratory services for drug discovery and disease research.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Axol Bioscience Comparables
Compare Axol Bioscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ncardia | 90% | |
| iXCells Biotechnologies | 87% | |
| BrainXell | 85% |
Axol Bioscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Jan 13, 2026 | ||||
| Grant | Dec 6, 2024 | ||||
| Series A Extension | Apr 7, 2022 | ||||
| Early Funding | Mar 16, 2021 | ||||
| Grant | Dec 1, 2020 | ||||
Private Equity | Aug 15, 2017 |
Key People
Founding team and executive leadership
Axol Bioscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Par Equity | Series A Extension, Early Funding |
| European Commission | Grant |
| Meltwind Advisory | Series A Extension, Private Equity, Early Funding |
| Roslin Foundation | Early Funding |
| Intuitive Investments Group Plc | Early Funding |
| Calculus Capital | Private Equity, Series A Extension, Early Funding |
| Scottish Investment Bank (Scottish Enterprise) | Early Funding, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 31, 2026
Partnering with ALS TDI and LifeArc on iPSC-derived motor neuron models.
- Mar 3, 2026
Developing a quantum-enabled brain-on-chip platform with multiple partners.
Recent news
Latest coverage and updates
- recognized_asJun 26, 2026
Axolbio recognized as Sunday Times Scotland Fast 50.
Axol Bioscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Axol Bioscience's valuation, stock price, and market status.
Is Axol Bioscience a public or private company?
Axol Bioscience is a private company.
What is the current stock price of Axol Bioscience?
Axol Bioscience is a private company with no public stock price. No recent secondary market data is available.
How much is Axol Bioscience worth (valuation)?
Axol Bioscience's valuation is estimated at $36.0M based on funding round data.
Can I buy Axol Bioscience stock?
Axol Bioscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Axol Bioscience's last funding round?
Axol Bioscience's most recent funding round was Early Funding on March 17, 2021.
Who are the main investors in Axol Bioscience?
Key investors in Axol Bioscience include Par Equity, Calculus Capital, BroadOak Capital Partners.
Will Axol Bioscience IPO soon?
No public IPO plans have been announced for Axol Bioscience.
How can I track Axol Bioscience secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Axol Bioscience's secondary market activity and sign up for updates.